Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929934 | 0.77 | HTT (0.42) | HTTPOLBMEN1KMT2AGALR3 | |
| SCHEMBL4521878 | 0.76 | TDP1 (0.43) | HTTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8665223 | 0.72 | ALDH1A1 (0.41) | HTTPOLBMEN1KMT2AGALR3 | |
| SCHEMBL8487056 | 0.71 | ALDH1A1 (0.59) | HTTPOLBKMT2AALDH1A1TSHR | |
| SCHEMBL644322 | 0.69 | SLC7A5 (0.36) | — | |
| SCHEMBL4457410 | 0.69 | HTT (0.48) | HTTPOLBMEN1KMT2AGALR3 | |
| SCHEMBL6643645 | 0.69 | ALDH1A1 (0.52) | HTTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL643184 | 0.69 | KCNH2 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL14477748 | 0.68 | HSD17B10 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL7823977 | 0.68 | KMT2A (0.53) | HTTPOLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
| EP-1988925-A2 | BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES | MALLINCKRODT, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100563-A2 | BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES | MALLINCKRODT INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100563-A2 | BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES | MALLINCKRODT INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | SPR, QDPR, SLC40A1 | HTT 648/4885POLB 3908/4885MEN1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.